The purpose of this study is to evaluate the efficacy and safety of HRS-9231 for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI); to explore the effective dose of HRS-9231 for CNS MRI; and to explore the population pharmacokinetic characteristics of HRS-9231 in CNS MRI subjects
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Enrollment
78
HRS-9231
Gadobutrol
People's Hospital, Peking University
Beijing, Beijing Municipality, China
Calculate the Contrast-to-Noise Ratio (CNR) based on the Signal Intensity (SI) of CNS lesions in MRI images after receiving HRS-9231 or the control drug (Gadobutrol)
Time frame: 1 day procedure
Medical applicability of MRI imaging for CNS lesions after receiving HRS-9231 or the control drug (Gadobutrol).
Time frame: 1 day procedure
Number, size, and location of CNS lesions in MRI images after receiving HRS-9231 or the control drug.
Time frame: 1 day procedure
Visualization scores for CNS lesions in MRI images after receiving HRS-9231 or the control drug (Gadobutrol): boundary delineation, internal morphology, and contrast enhancement.
Time frame: 1 day procedure
HRS-9231 plasma concentration and population pharmacokinetic parameters (such as clearance, apparent volume of distribution, etc.).
Time frame: 1 day procedure
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.